<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096092</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF 19.05</org_study_id>
    <nct_id>NCT04096092</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Teicoplanin in Intensive Care and Haematology Patients</brief_title>
  <acronym>PLATO</acronym>
  <official_title>A Population PK Study Into Teicoplanin in Intensive Care and Haematology Patients - a Strategy Towards Model Informed Precision Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Characterize teicoplanin PK in critically ill patients with a specific focus on alterations&#xD;
      of exposure due to variability in renal function.&#xD;
&#xD;
      In a prospective, observational, open-label study the investigators aim to define PK of free&#xD;
      drug concentrations of teicoplanine in ICU and heamatology patients and define a PK model for&#xD;
      Bayesian dose individualization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bacterial infection with coagulase-negative staphylococci (CNS) or methicillin resistant and&#xD;
      sensitive staphylococcus aureus(MRSA/MSSA) indicates poor prognosis and increased mortality&#xD;
      in critically ill patients.&#xD;
&#xD;
      With the current emergence of glycopeptide-intermediate sensitive Staphylococcus aureus&#xD;
      strains, personalized dosing of teicoplanin is of utmost importance to preserve the current&#xD;
      therapeutic armamentarium.&#xD;
&#xD;
      Teicoplanin is considered equipotent to vancomycin, albeit safer with minimal nephrotoxicity.&#xD;
      It is estimated that 50% of all critically ill patients treated with teicoplanin does not&#xD;
      reach target exposure. This is the major driver for treatment failure and development of&#xD;
      resistance and dose individualization will overcome this problem.&#xD;
&#xD;
      Our project is aimed at developing and implementing a personalized dosing strategy for&#xD;
      teicoplanin, to prevent development of glycopeptide resistance and allow safe treatment of&#xD;
      glycopeptide intermediate sensitive bacteria.&#xD;
&#xD;
      In a prospective clinical study, critically ill patients (defined as ICU and hematology&#xD;
      patients) who receive teicoplanin as standard care for antimicrobial treatment will be&#xD;
      eligible for inclusion. Minimally invasive blood sampling for pharmacokinetic analysis will&#xD;
      be retrieved through an indwelling central venous catheter or an arterial line (9 samples per&#xD;
      patient). Teicoplanin total and free drug concentrations will be measured using a validated&#xD;
      analytical assay. A total of 30 patients will be included.&#xD;
&#xD;
      We will develop a population PK model using nonlinear mixed effects modelling for total and&#xD;
      unbound teicoplanin to characterize the magnitude of inter-individual variability in PK&#xD;
      parameters (clearance, distribution volume), and to identify patient-derived characteristics&#xD;
      that can predict such variability in a critically ill patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total drug clearance</measure>
    <time_frame>4 days</time_frame>
    <description>Pharmacokinetic curves will be taken</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution</measure>
    <time_frame>4 days</time_frame>
    <description>Pharmacokinetic curves will be taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>4 days</time_frame>
    <description>Pharmacokinetic curves will be taken</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bacterial Infections</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All critically ill patients (defined as ICU and hematology patients) with a suspected or&#xD;
        proven bacterial infection who are already treated with teicoplanin as a part of routine&#xD;
        clinical care are eligible for inclusion. A total of 30 patients will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient is admitted to the ICU of the haematology department&#xD;
&#xD;
          2. The patient is at least 18 years of age on the day of inclusion&#xD;
&#xD;
          3. Is managed with a central venous catheter or arterial line&#xD;
&#xD;
          4. Is treated with teicoplanin as a part of standard care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has previously participated in this study&#xD;
&#xD;
          2. Patient is admitted to the haematology department and receives any form of RRT other&#xD;
             than continuous venovenous hemofiltration (CVVH).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger JM Brüggemann, PharmD, PhD</last_name>
      <phone>+31243617744</phone>
      <email>Roger.Brüggemann@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Eveline Wallenburg, PharmD</last_name>
      <phone>+31243617744</phone>
      <email>Eveline.Wallenburg@radboudumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Roger JM Brüggemann, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Teicoplanin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Critically ill</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

